Ownership and insider activity for Eupraxia Pharmaceuticals Inc. (EPRX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Price
| Price | $8.09 |
| Market Cap | $271M |
| Exchange | NASDAQ |
| Country | CA |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.0M | $823481 | $1.2M | $150126 | $20.9M | $24.7M | $14.6M | $33.1M | $80.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | $9.0M | 0 | 0 | 0 | 0 |
| Receivables | $1.3M | $1.5M | 0 | 0 | 0 | 0 | $143516 | $228872 | $674226 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $5.5M | $2.5M | $2.6M | $1.1M | $30.6M | $25.2M | $14.9M | $34.4M | $85.1M |
| Property, Plant & Equipment | $419438 | $435468 | $646210 | $315337 | $589068 | $718608 | $343520 | $424916 | $987126 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $5.9M | $2.9M | $3.3M | $1.5M | $31.2M | $25.9M | $15.3M | $34.9M | $86.2M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | $3.8M | $11.6M | $12.5M | $94916 | $107528 | $7.8M | 0 | 0 |
| Total Current Liabilities | $730683 | $14.3M | $20.7M | $22.5M | $2.3M | $4.1M | $14.6M | $3.1M | $5.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | $9.7M | $11.9M | 0 | 0 | 0 |
| Total Liabilities | $735815 | $14.3M | $21.4M | $23.1M | $12.1M | $16.1M | $14.6M | $3.1M | $5.7M |
| Retained Earnings | -$20.1M | -$40.0M | -$47.2M | -$51.2M | -$74.3M | -$104.6M | -$79.4M | -$131.0M | -$169.6M |
| Total Equity | $6.0M | -$11.1M | -$17.7M | -$21.2M | $20.0M | $10.5M | $1.7M | $33.4M | $82.0M |
| Total Debt | $12474 | $3.8M | $11.9M | $12.8M | $10.0M | $12.2M | $7.9M | $71859 | $154362 |
| Net Debt | -$4.0M | $3.0M | $10.8M | $12.6M | -$19.9M | -$12.6M | -$6.7M | -$33.0M | -$80.4M |
| Working Capital | $4.8M | -$11.9M | -$18.0M | -$21.4M | $28.3M | $21.0M | $323137 | $31.3M | $79.5M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 16.00 |
Profitability
| Return on Equity | -45.29% |
| Return on Invested Capital | -43.07% |
| Return on Assets | -35.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AARD · GNFT · IVA · MDWD · NAUT · NTHI · OBIO
Explore sector: Healthcare · Biotechnology
More sections of EPRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks